Overview

This trial is active, not recruiting.

Condition glucose intolerance
Sponsor Yale University
Start date January 2002
End date June 2003
Trial size 46 participants
Trial identifier NCT00589355, 12110

Summary

The goal of this study is to determine whether markers of vascular inflammation (such as c-reactive protein) can predict endothelial dysfunction (as measured by flow-mediated dilation) in postmenopausal women with glucose intolerance compared to normal controls.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective cross-sectional
Arm
postmenopausal women with glucose intolerance (either pre-diabetes or diet-controlled diabetes)
postmenopausal women with normal glucose tolerance

Primary Outcomes

Measure
c-reactive protein
time frame: performed after screening evaluation

Secondary Outcomes

Measure
flow-mediated dilation of brachial artery
time frame: performed twice after screening visit
sex steroids
time frame: performed after screening visit

Eligibility Criteria

Female participants from 40 years up to 65 years old.

Inclusion Criteria: - healthy postmenopausal women - ages 40-65 Exclusion Criteria: - smokers - diabetes requiring medication

Additional Information

Official title C-Reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance
Principal investigator Barbara I Gulanski, MD, MPH
Trial information was received from ClinicalTrials.gov and was last updated in December 2007.
Information provided to ClinicalTrials.gov by Yale University.